Literature DB >> 20477746

Disproportionate impact of pandemic (H1N1) 2009 influenza on Indigenous people in the Top End of Australia's Northern Territory.

Shaun M Flint1, Joshua S Davis, Jiunn-Yih Su, Erin P Oliver-Landry, Benjamin A Rogers, Aaron Goldstein, Jane H Thomas, Uma Parameswaran, Colin Bigham, Kevin Freeman, Paul Goldrick, Steven Y C Tong.   

Abstract

OBJECTIVE: To describe the impact of pandemic (H1N1) 2009 influenza (nH1N1) on Indigenous people in the Top End of the Northern Territory at community, hospital and intensive care unit (ICU) levels. DESIGN, SETTING AND PARTICIPANTS: We analysed influenza notifications for the Top End from 1 June to 31 August 2009, as well as data on patients admitted through Top End emergency departments with an influenza-like illness. In addition, data on patients with nH1N1 who were admitted to Royal Darwin Hospital (RDH) and the RDH ICU were prospectively collected and analysed. MAIN OUTCOME MEASURES: Age-adjusted notification rates for nH1N1 cases, Top End hospital admission rates for patients with nH1N1 and RDH ICU admission rates for patients with nH1N1, stratified by Indigenous status.
RESULTS: There were 918 nH1N1 notifications during the study period. The age-adjusted hospital admission rate for nH1N1 was 82 per 100 000 (95% CI, 68-95) estimated resident population (ERP) overall, with a markedly higher rate in the Indigenous population compared with the non-Indigenous population (269 per 100 000 versus 29 per 100 000 ERP; adjusted incidence rate ratio, 12 [95% CI, 7.8-18]). Independent predictors of ICU admission compared with hospitalisation were hypoxia (adjusted odds ratio [aOR], 4.5; CI, 1.5-13.1) and chest x-ray infiltrates (aOR, 4.3; CI, 1.5-12.6) on hospital admission.
CONCLUSIONS: Pandemic (H1N1) 2009 influenza had a disproportionate impact on Indigenous Australians in the Top End, with hospitalisation rates higher than those reported elsewhere in Australia and overseas. These findings have implications for planning hospital and ICU capacity during an influenza pandemic in regions with large Indigenous populations. They also confirm the need to improve health and living circumstances and to prioritise vaccination in this population.

Entities:  

Mesh:

Year:  2010        PMID: 20477746

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  45 in total

1.  Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002 and FLU 003 studies.

Authors:  Dominic E Dwyer
Journal:  Vaccine       Date:  2011-07-22       Impact factor: 3.641

Review 2.  Impact of H1N1 on socially disadvantaged populations: summary of a systematic review.

Authors:  Andrea C Tricco; Erin Lillie; Charlene Soobiah; Laure Perrier; Sharon E Straus
Journal:  Influenza Other Respir Viruses       Date:  2013-09       Impact factor: 4.380

3.  Safety, equity and monitoring: a review of the gaps in maternal vaccination strategies for Aboriginal and Torres Strait Islander women.

Authors:  Lisa McHugh; Kristy Crooks; Amy Creighton; Michael Binks; Ross M Andrews
Journal:  Hum Vaccin Immunother       Date:  2019-09-06       Impact factor: 3.452

4.  Baseline incidence of adverse birth outcomes and infant influenza and pertussis hospitalisations prior to the introduction of influenza and pertussis vaccination in pregnancy: a data linkage study of 78 382 mother-infant pairs, Northern Territory, Australia, 1994-2015.

Authors:  L McHugh; R M Andrews; B Leckning; T Snelling; M J Binks
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

5.  Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities.

Authors:  Sergio Quiñones-Parra; Emma Grant; Liyen Loh; Thi H O Nguyen; Kristy-Anne Campbell; Steven Y C Tong; Adrian Miller; Peter C Doherty; Dhanasekaran Vijaykrishna; Jamie Rossjohn; Stephanie Gras; Katherine Kedzierska
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-06       Impact factor: 11.205

6.  Surveillance of hospitalizations with pandemic A(H1N1) 2009 influenza infection in Queensland, Australia.

Authors:  Hai Phung; Frank Beard; Christine Selvey; Ranil Appuhamy; Frances Birrell
Journal:  Western Pac Surveill Response J       Date:  2011-05-30

Review 7.  Two years after pandemic influenza A/2009/H1N1: what have we learned?

Authors:  Vincent C C Cheng; Kelvin K W To; Herman Tse; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

8.  Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses.

Authors:  Sophie A Valkenburg; Tracy M Josephs; E Bridie Clemens; Emma J Grant; Thi H O Nguyen; George C Wang; David A Price; Adrian Miller; Steven Y C Tong; Paul G Thomas; Peter C Doherty; Jamie Rossjohn; Stephanie Gras; Katherine Kedzierska
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-31       Impact factor: 11.205

9.  CD8+ T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph.

Authors:  Luca Hensen; Patricia T Illing; E Bridie Clemens; Thi H O Nguyen; Marios Koutsakos; Carolien E van de Sandt; Nicole A Mifsud; Andrea T Nguyen; Christopher Szeto; Brendon Y Chua; Hanim Halim; Simone Rizzetto; Fabio Luciani; Liyen Loh; Emma J Grant; Phillipa M Saunders; Andrew G Brooks; Steve Rockman; Tom C Kotsimbos; Allen C Cheng; Michael Richards; Glen P Westall; Linda M Wakim; Thomas Loudovaris; Stuart I Mannering; Michael Elliott; Stuart G Tangye; David C Jackson; Katie L Flanagan; Jamie Rossjohn; Stephanie Gras; Jane Davies; Adrian Miller; Steven Y C Tong; Anthony W Purcell; Katherine Kedzierska
Journal:  Nat Commun       Date:  2021-05-18       Impact factor: 14.919

10.  Broad-Based Influenza-Specific CD8+ T Cell Response without the Typical Immunodominance Hierarchy and Its Potential Implication.

Authors:  Miaojuan Huang; Rong Xu; Cristina Triffon; Nicole Mifsud; Weisan Chen
Journal:  Viruses       Date:  2021-06-05       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.